An online article reported that PRL3-zumab extended the life expectancies of a late-Stage IV Gastric cancer patient by years, showing PRL3-zumab could stand behind PD1-PDL1 non-responders as a rescue immunotherapy 37. Here, PTP4A3 is linked to gastric cancer.